Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors

Gene Therapy

Volumn 5, Issue 2, 1998, Pages 160-165

  Advani, S J ^a   Sibley, G S ^a   Song, P Y ^a   Hallahan, D E ^a   Kataoka, Y ^a   Roizman, B ^b   Weichselbaum, R R ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Attenuated herpesviruses; Malignant gliomas; Mouse models

Indexed keywords

VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; DNA PROBE; GENE THERAPY; GENETIC ENGINEERING; GLIOBLASTOMA; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS REPLICATION; XENOGRAFT;

ANIMALIA; DNA VIRUSES; HERPES; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 0031909185     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300546     Document Type: Article

References (23)

1. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980; 30: 907-911.
2. Wallner KE et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989; 16: 1405-1409.
3. Markert JM, Malick A, Coen DM, Martuza RL. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir Neurosurgery 1993; 32: 597-603.
4. Martuza RL et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856.
5. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 1994; 54: 3963-3966.
6. Andreansky SS et al. The application of genetically engineered herpes simplex viruses to the treatment of experimental animal tumors. Proc Natl Acad Sci USA 1996; 92: 11313-11318.
7. Chambers R et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci USA 1995; 92: 1411-1415.
8. Kesari S et al. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest 1995; 73: 636-648.
9. Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med 1995; 1: 938-943.
10. Valyi-Nagy T et al. The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. J Gen Virol 1994; 75: 2059-2063.
11. γ134.5 deletion mutants in rodent models. J Clin Invest 1993; 91: 2837-2843.
12. γ134.5, a gene nonessential for growth in culture. Science 1990; 250: 1261-1266.
13. γ134.5 gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells. Proc Natl Acad Sci USA 1992; 89: 3266-3270.
14. γ134.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage Proc Natl Acad Sci USA 1994; 91: 5247-5251.
15. - mutants of herpes simplex virus 1. Proc Natl Acad Sci USA 1995; 92: 10516-10520.
16. - mutant of herpes simplex virus 1. J Virol 1997; 71: 5560-5569.
17. Loeffler JS et al. The treatment of recurrent brain metastasis with stereotactic radiosurgery. J Clin Oncol 1990; 8: 576-582
18. Lunsford LD, Flickinger J, Lindner G, Maitz A. Stereotactic radiosurgery of the brain using the first United States 201 cobalt-60 source gamma knife Neurosurgery 1989; 24: 151-159
19. Larson DA et al. Gamma knife for glioma: selection factors and survival. Int J Radiat Oncol Biol Phys 1996; 36: 1045-1053.
20. Liang KY, Zeger SL. Longitudinal analysis using generalized linear model. Biometrika 1986; 73: 13-22.
21. γ134.5 gene of herpes simplex virus to preclude the premature shutoff of total protein synthesis in infected human cells J Virol 1996; 70 84-90.
22. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex virus R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988; 158: 602-614.
23. Milliken GA. Analysis of repeated measures design in statistical methodology in the pharmaceutical sciences. Berry DA (ed). Marcel Dekker: New York, 1990.